Purespring Therapeutics
Series B in 2024
Purespring Therapeutics specializes in developing gene therapies targeting kidney diseases, focusing on podocytes, specialized kidney cells. It is one of the first globally to use AAV gene therapy specifically for kidney conditions.
Resolution Therapeutics
Series B in 2024
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapy aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the therapeutic potential of macrophages to address conditions such as liver cirrhosis, thereby seeking to fulfill the significant unmet regenerative needs in the treatment of chronic liver ailments. Through its innovative approach, Resolution Therapeutics aims to contribute to advancements in regenerative medicine and improve patient outcomes in the realm of liver health.
iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.
Freeline Therapeutics
Acquisition in 2023
Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.
SwanBio Therapeutics
Venture Round in 2023
SwanBio Therapeutics is a biotechnology company dedicated to developing innovative therapies for neurological diseases. The firm specializes in genetically defined treatments aimed at addressing various neurological disorders, including adrenomyeloneuropathy (AMN). By focusing on the development and commercialization of its therapeutic technology, SwanBio seeks to provide effective solutions that can significantly improve clinical outcomes for patients affected by such conditions.
Beacon Therapeutics
Series A in 2023
Beacon Therapeutics is a biotechnology company focused on developing gene therapies for rare retinal diseases that cause blindness. Utilizing its proprietary platform, Beacon aims to restore and improve vision in patients suffering from these debilitating conditions. Currently operating at the clinical stage, the company's primary focus lies within ophthalmology, with the goal of transforming lives by treating severe eye diseases.
Mosaic Therapeutics
Series A in 2023
Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.
SwanBio Therapeutics
Series B in 2022
SwanBio Therapeutics is a biotechnology company dedicated to developing innovative therapies for neurological diseases. The firm specializes in genetically defined treatments aimed at addressing various neurological disorders, including adrenomyeloneuropathy (AMN). By focusing on the development and commercialization of its therapeutic technology, SwanBio seeks to provide effective solutions that can significantly improve clinical outcomes for patients affected by such conditions.
OMass Therapeutics
Series B in 2022
OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.
Resolution Therapeutics
Series A in 2022
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapy aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the therapeutic potential of macrophages to address conditions such as liver cirrhosis, thereby seeking to fulfill the significant unmet regenerative needs in the treatment of chronic liver ailments. Through its innovative approach, Resolution Therapeutics aims to contribute to advancements in regenerative medicine and improve patient outcomes in the realm of liver health.
Freeline Therapeutics
Post in 2022
Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.
Founded in 2017, Anaveon develops biologics that modulate cytokine function to provide therapeutic benefits for cancer patients and those with immune-related disorders. The company focuses on IL-2 complexes that selectively enhance effector T cell functions, acting as effective immune adjuvants.
Quell Therapeutics
Series B in 2021
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.
Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Clade Therapeutics
Series A in 2021
Founded in 2020, Clade Therapeutics is a biopharmaceutical company headquartered in Cambridge, Massachusetts. It specializes in developing scalable, off-the-shelf stem-cell-based therapies to treat cancer, autoimmune diseases, and other life-threatening conditions.
Gyroscope
Series C in 2021
Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.
Quell Therapeutics
Series A in 2021
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.
Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Resolution Therapeutics
Series A in 2020
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapy aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the therapeutic potential of macrophages to address conditions such as liver cirrhosis, thereby seeking to fulfill the significant unmet regenerative needs in the treatment of chronic liver ailments. Through its innovative approach, Resolution Therapeutics aims to contribute to advancements in regenerative medicine and improve patient outcomes in the realm of liver health.
Purespring Therapeutics
Series A in 2020
Purespring Therapeutics specializes in developing gene therapies targeting kidney diseases, focusing on podocytes, specialized kidney cells. It is one of the first globally to use AAV gene therapy specifically for kidney conditions.
Achilles Therapeutics
Series C in 2020
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.
Neogene Therapeutics
Series A in 2020
Neogene Therapeutics, Inc., founded in 2018 and based in New York, develops innovative T cell therapies aimed at treating cancer. The company specializes in creating personalized engineered T cells that target mutated proteins, known as neo-antigens, found in cancer cells as a result of DNA mutations. By leveraging advanced technologies, Neogene isolates neo-antigen specific T cell receptor genes from tumor biopsies, which are routinely collected during cancer treatment. These tumor-infiltrating lymphocytes often express T cell receptors that can recognize and attack cancer cells displaying neo-antigens. Utilizing state-of-the-art DNA sequencing, synthesis, and genetic screening, Neogene's proprietary platform enables the identification of these specific T cell receptors with high sensitivity and at scale, ultimately enhancing the efficacy of cancer treatments.
SwanBio Therapeutics
Series A in 2020
SwanBio Therapeutics is a biotechnology company dedicated to developing innovative therapies for neurological diseases. The firm specializes in genetically defined treatments aimed at addressing various neurological disorders, including adrenomyeloneuropathy (AMN). By focusing on the development and commercialization of its therapeutic technology, SwanBio seeks to provide effective solutions that can significantly improve clinical outcomes for patients affected by such conditions.
OMass Therapeutics
Series A in 2020
OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.
Freeline Therapeutics
Series C in 2019
Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.
Azeria Therapeutics
Series B in 2019
Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, focused on developing innovative treatments for hormone-resistant breast and prostate cancer patients. Founded in 2017, the company is dedicated to creating a pipeline of small molecules that selectively inhibit pioneer factors, addressing significant unmet clinical needs in cancer treatment. By targeting these specific mechanisms, Azeria aims to enhance the effectiveness of therapies for patients facing these challenging cancer types.
Gyroscope
Series B in 2019
Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.
Achilles Therapeutics
Series B in 2019
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.
Quell Therapeutics
Series A in 2019
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.
Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Founded in 2017, Anaveon develops biologics that modulate cytokine function to provide therapeutic benefits for cancer patients and those with immune-related disorders. The company focuses on IL-2 complexes that selectively enhance effector T cell functions, acting as effective immune adjuvants.
Orbit Biomedical
Seed Round in 2019
Orbit Biomedical Limited is a retinal gene therapy company focused on developing innovative surgical devices and procedures for treating specific retinal conditions. Founded in 2018 and headquartered in Stevenage, United Kingdom, with an additional location in Ambler, Pennsylvania, the company aims to revolutionize gene and cell therapy by establishing a new standard for precise and targeted surgical delivery. Orbit Biomedical emphasizes improving the accuracy, safety, and consistency of therapeutic delivery, thereby enhancing patient outcomes. In addition to its medical devices, the company has designed a comprehensive training process for surgeons and clinical staff, utilizing various educational modalities to ensure proficiency in its procedures. Through these efforts, Orbit Biomedical seeks to transform the landscape of gene therapy treatment and improve the management of chronic retinal diseases.
OMass Therapeutics
Series A in 2018
OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.
Freeline Therapeutics
Series B in 2018
Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.
SwanBio Therapeutics
Seed Round in 2018
SwanBio Therapeutics is a biotechnology company dedicated to developing innovative therapies for neurological diseases. The firm specializes in genetically defined treatments aimed at addressing various neurological disorders, including adrenomyeloneuropathy (AMN). By focusing on the development and commercialization of its therapeutic technology, SwanBio seeks to provide effective solutions that can significantly improve clinical outcomes for patients affected by such conditions.
Resolution Therapeutics
Seed Round in 2017
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapy aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the therapeutic potential of macrophages to address conditions such as liver cirrhosis, thereby seeking to fulfill the significant unmet regenerative needs in the treatment of chronic liver ailments. Through its innovative approach, Resolution Therapeutics aims to contribute to advancements in regenerative medicine and improve patient outcomes in the realm of liver health.
Autolus Therapeutics is a biopharmaceutical company based in London, England, focused on developing next-generation programmed T cell therapies for cancer treatment. Founded in 2014 by Tim Funnell and Martin Pule, the company has established a clinical-stage pipeline that includes several innovative therapies, such as Obe-cel (obecabtagene autoleucel) and others designated as AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Through its research and development efforts, Autolus aims to advance the field of cancer immunotherapy and improve outcomes for patients battling various types of cancer.
Nightstar Therapeutics
Series C in 2017
Nightstar Therapeutics is a clinical-stage gene therapy company based in London, United Kingdom, specializing in the development of innovative one-time treatments for rare inherited retinal diseases. The company is advancing several product candidates, including its lead candidate NSR-REP1, which is in phase 3 clinical development for choroideremia. Additionally, Nightstar is working on NSR-RPGR, currently in phase 2/3 trials for X-linked retinitis pigmentosa, as well as NSR-BEST1. The company is also developing NSR-ABCA4, which is in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address significant unmet medical needs in the field of retinal disorders.
Gyroscope
Seed Round in 2017
Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.
Achilles Therapeutics
Seed Round in 2016
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.
Cambridge Epigenetix
Series B in 2016
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Freeline Therapeutics
Series A in 2015
Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.
Nightstar Therapeutics
Series B in 2015
Nightstar Therapeutics is a clinical-stage gene therapy company based in London, United Kingdom, specializing in the development of innovative one-time treatments for rare inherited retinal diseases. The company is advancing several product candidates, including its lead candidate NSR-REP1, which is in phase 3 clinical development for choroideremia. Additionally, Nightstar is working on NSR-RPGR, currently in phase 2/3 trials for X-linked retinitis pigmentosa, as well as NSR-BEST1. The company is also developing NSR-ABCA4, which is in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address significant unmet medical needs in the field of retinal disorders.
Blue Earth Diagnostics
Series B in 2015
Blue Earth Diagnostics Limited is a molecular imaging diagnostics company focused on developing and commercializing innovative positron emission tomography (PET) imaging agents for cancer management. The company specializes in detecting and localizing prostate cancer, particularly in men experiencing biochemical recurrence, through its flagship product, Axumin. Additionally, Blue Earth is advancing a range of prostate-specific membrane antigen (PSMA)-targeting radiohybrid agents, which are investigational theranostic compounds with potential applications in both imaging and treatment of prostate cancer. The company aims to address significant unmet medical needs in oncology, enhancing the efficiency of diagnosis and treatment for patients with prostate and brain cancers. Founded in 2013 and headquartered in Oxford, United Kingdom, Blue Earth Diagnostics also has offices in Burlington, Massachusetts, and Dublin, Ireland. It operates as a subsidiary of Bracco Imaging S.p.A.
Autolus Therapeutics is a biopharmaceutical company based in London, England, focused on developing next-generation programmed T cell therapies for cancer treatment. Founded in 2014 by Tim Funnell and Martin Pule, the company has established a clinical-stage pipeline that includes several innovative therapies, such as Obe-cel (obecabtagene autoleucel) and others designated as AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Through its research and development efforts, Autolus aims to advance the field of cancer immunotherapy and improve outcomes for patients battling various types of cancer.
Cambridge Epigenetix
Series A in 2014
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Nightstar Therapeutics
Series A in 2014
Nightstar Therapeutics is a clinical-stage gene therapy company based in London, United Kingdom, specializing in the development of innovative one-time treatments for rare inherited retinal diseases. The company is advancing several product candidates, including its lead candidate NSR-REP1, which is in phase 3 clinical development for choroideremia. Additionally, Nightstar is working on NSR-RPGR, currently in phase 2/3 trials for X-linked retinitis pigmentosa, as well as NSR-BEST1. The company is also developing NSR-ABCA4, which is in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address significant unmet medical needs in the field of retinal disorders.
Kesmalea Therapeutics is a biotechnology company specializing in the discovery of novel protein degraders. It offers an alternative approach for therapeutics with 'PROTAC-like' actions, aiming to transform large protein degraders into small molecules for targeted protein degradation.
Kesmalea Therapeutics is a biotechnology company specializing in the discovery of novel protein degraders. It offers an alternative approach for therapeutics with 'PROTAC-like' actions, aiming to transform large protein degraders into small molecules for targeted protein degradation.